NMPA Approves New Whitening Ingredient under CSAR Framework

On November 4, 2024, China’s National Medical Products Administration (NMPA) approved the registration of a new cosmetic ingredient, Isobutylamido Thiazolyl Resorcinol (also known as Thiamidol 630).

Developed by Beiersdorf AG in Germany, this ingredient is the first whitening agent approved under China’s Cosmetic Supervision and Administration Regulation (CSAR), which has been in effect since January 1, 2021.

The approval permits its use in leave-on cosmetic products, excluding those that may involve inhalation exposure, marking a significant step forward in the regulatory process for innovative cosmetic ingredients in China.

Significance of Isobutylamido Thiazolyl Resorcinol Approval

The approval of Isobutylamido Thiazolyl Resorcinol is a milestone under the CSAR framework, which introduced a registration and monitoring system to replace the prior approval process for high-risk cosmetic ingredients. This system emphasizes safety and efficacy, requiring new ingredients like this whitening agent to undergo comprehensive validation before registration.

Following approval, a three-year safety monitoring period will apply, during which Beiersdorf must continue to evaluate the ingredient’s safety and report findings to the NMPA. Upon successful completion of this period, the ingredient may be included in the Inventory of Existing Cosmetic Ingredients in China (IECIC), facilitating broader use in formulations.

Implications for Compliance and Regulatory Affairs

The introduction of this new whitening agent underscores the importance of adhering to CSAR requirements for ingredient approval. Compliance and regulatory affairs managers should note the following:

1) Robust data requirements: Thorough safety and efficacy data must be prepared and submitted in alignment with NMPA guidelines. Post-registration monitoring is equally critical for continued compliance.

2) Evolving regulations: Regularly monitoring updates from the NMPA is essential to remain aligned with China’s regulatory expectations.

3) Collaboration with experts: Leveraging the expertise of local regulatory professionals can streamline the navigation of CSAR’s complex requirements.

Opportunities for Foreign Companies

The approval of Isobutylamido Thiazolyl Resorcinol demonstrates China’s commitment to balancing innovation with consumer safety. This ingredient offers a new option for the development of advanced skin-whitening products, bolstering research and development within the cosmetics industry.

Foreign companies looking to enter or expand within the Chinese market should view this development as both an opportunity and a reminder of the importance of rigorous compliance with CSAR’s regulations.

This regulatory milestone not only benefits cosmetic manufacturers but also reinforces the NMPA’s dedication to fostering safe, effective, and innovative cosmetic products for consumers.

Furthermore Information

To read the NMPA’s announcement concerning the Isobutylamido Thiazolyl Resorcinol, please click here.

Learn more about China’s CSAR framework, which has been in effect since January 2021, please click here.

Learn how Cisema can support your organization regarding cosmetics registration and filing in China here.